Skip to main navigation Skip to search Skip to main content

Progress toward overcoming hypoxia-induced resistance to solid tumor therapy

  • College of Medicine, Drexel University

Research output: Contribution to journalArticlepeer-review

99 Scopus citations

Abstract

Hypoxic tumors are associated with poor clinical outcome for multiple types of human cancer. This may be due, in part, to hypoxic cancer cells being resistant to anticancer therapy, including radiation therapy, chemotherapy, and targeted therapy. Hypoxia inducible factor 1, a major regulator of cellular response to hypoxia, regulates the expression of genes that are involved in multiple aspects of cancer biology, including cell survival, proliferation, metabolism, invasion, and angiogenesis. Here, we review multiple pathways regulated by hypoxia/hypoxia inducible factor 1 in cancer cells and discuss the latest advancements in overcoming hypoxia-mediated tumor resistance.
Original languageEnglish
Pages (from-to)253-264
Number of pages12
JournalCancer Management and Research
Volume7
DOIs
StatePublished - Aug 12 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Hif-1 apoptosis cancer chemoresistance signaling

Fingerprint

Dive into the research topics of 'Progress toward overcoming hypoxia-induced resistance to solid tumor therapy'. Together they form a unique fingerprint.

Cite this